stockrow
Saturday 7 November 2026
Export IBIO’s income statement to Excel — free account
iBio, Inc.
IBIO Healthcare Biotechnology
iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.
- Revenue
- +100.0%
- EPS
- +80.5%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow IBIO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (65.70%) | (62.09%) | (70.22%) | (54.50%) |
+8 more TTM periods Free account |
|
| (54.04%) | (52.61%) | (57.47%) | (45.35%) | ||
ROIC |
0.00% | (660.56%) | (412.24%) | (177.64%) | |
Return on Tangible Assets |
(39.54%) | (37.28%) | (48.59%) | (41.95%) | |
Average Days of Receivables |
0.00 | — | — | 35.15 | |
Free Cash Flow per Share |
(0.23) | (0.19) | (0.19) | (0.33) | |
Free Cash Flow |
(23.80) | (22.16) | (19.19) | (17.30) | |
Capital Expenditures |
(0.58) | (0.56) | (0.56) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(13.70%) | (14.55%) | (17.56%) | (16.27%) | |
Accounts Receivable Turnover |
0.00 | — | — | 0.10 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,564.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,539.26% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 213.04% | |
Interest Coverage |
(663.04) | (202.51) | (145.56) | (107.05) | |
Operating CF/Net income |
0.70 | 0.78 | 0.75 | 0.86 | |
Depreciation/Fixed assets |
0.27 | 0.27 | 0.29 | 0.35 | |
Capex/Depreciation |
(0.69) | (0.62) | (0.56) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.22) | (0.18) | (0.19) | (0.33) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.07 |
Columns are period end dates · fundamentals updated 26 Oct 2026